Related Experiment Video
Updated: Aug 26, 2026
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation
Melinda S Sharkey1, Gregory Lizée, Monica I Gonzales
1Surgery Branch, National Cancer Institute, Center for Cancer Research, NIH, Bethesda, MD 20892, USA.
Abstract:
The potential of antigen-directed cancer immunotherapy has not been fully realized, perhaps because many commonly targeted tumor associated proteins are not essential to maintaining the malignant cell phenotype. A constitutively activating mutation in the signaling molecule BRAF is expressed frequently in melanomas and may play an important role in the biology of this disease. A 29-mer B-Raf peptide incorporating the V599E mutation was used for in vitro stimulation of lymphocytes derived from melanoma patients, generating MHC class II-restricted CD4(+) T cells specific for this peptide as well as for melanoma cells expressing B-Raf V599E. Mutated B-Raf exemplifies targets that may be ideal for immunotherapy.
Insights
Targeting mutated BRAF in melanoma shows promise for cancer immunotherapy. Researchers generated T cells specific for the mutated BRAF protein, demonstrating its potential as an ideal therapeutic target.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Antigen-directed cancer immunotherapy effectiveness is limited by targeting non-essential tumor proteins.
- BRAF mutations are common in melanoma and crucial for disease biology.
Purpose of the Study:
- To investigate the potential of targeting mutated BRAF for melanoma immunotherapy.
- To generate and characterize T cells specific for the BRAF V599E mutation.
Main Methods:
- A 29-mer B-Raf peptide with the V599E mutation was synthesized.
- In vitro stimulation of lymphocytes from melanoma patients using the mutated peptide.
- Characterization of MHC class II-restricted CD4(+) T cells.
Main Results:
- Generated CD4(+) T cells specific for the mutated B-Raf peptide.
- These T cells also recognized melanoma cells expressing B-Raf V599E.
- Demonstrated feasibility of targeting mutated BRAF via T cell activation.
Conclusions:
- Mutated BRAF is a viable and potentially ideal target for cancer immunotherapy in melanoma.
- Antigen-directed immunotherapy can be enhanced by targeting essential mutated proteins.
- This approach may overcome limitations of current immunotherapeutic strategies.
More Related Videos
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
10:01Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes
Published on: February 11, 2015